leisure time -WSS

leisure time

author：knowledge 2025-08-19 15:02:26 - browse：8

Adobe

The medical device industry is split on whether a proposed new Medicare reimbursement pathway will do anything to soothe their insurance coverage woes.

Device makers have long complained that the unclear, rocky road to payment kills innovative companies. So they were thrilled when the Trump administration proposed a rule that would have guaranteed four years of Medicare coverage of approved devices deemed “breakthroughs” by the Food and Drug Administration. They hoped private payers would follow suit. But in 2021, under a new administration and a push for more device scrutiny, the Centers for Medicare and Medicaid pulled back on the idea, promising a replacement that would streamline coverage for innovative devices while ensuring safe, high-quality care.

The pathway put forth last week, called Transitional Coverage for Emerging Technologies (TCET), is only a notice, not yet a rule that would grant CMS new powers. The program applies solely to devices that have earned a place in the FDA’s breakthrough device program, which was established to identify devices that the agency believed could provide “more effective” treatment or diagnosis of serious conditions than the current standard of care. But because those devices can be brought to market with less certainty in their benefits and risks than other products, experts said, the idea of automatic reimbursement was dicey.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： United colonoscopy coverage change 'may cost lives,' doctors say
Next article： Nearly two

WSS

Stem cell clinics for heart failure: buyer be wary

Military medical care influenced by rank and race, new study finds

CDC: Uninsured rate hit 'record low' right as states cut Medicaid

Wild otter attack leads to woman being airlifted to hospital, 2 others treated for injuries

A cyberattack has disrupted hospitals and health care in several states

Big Tobacco's 'harm reduction': Is it for real, or a sham?

Wikipedia

leisure time

explore

Medical leaders decry Supreme Court decision on affirmative action

Data integrity in scientific journals requires "effort" by publishers, institutions

The cancer drug shortage isn’t new — and neither are the solutions

Bird flu: Don't repeat Covid's 'health versus the economy' framing

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Addiction experts warn against a second 'war on drugs'

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Readers respond to H5N1 and livestock movements, and more

Supreme Court strikes down use of affirmative action

Treeline, Josh Bilenker's next biotech, is cloaked in mystery

Wikipedia

When prostate cancer spreads, where it goes matters

Anxious about a speech? A startup wants you to pop a minty cardiac drug

Case highlights the risks of experimental stem cell therapy

Big Tobacco's 'harm reduction': Is it for real, or a sham?

Nearly two

Bird flu: Don't repeat Covid's 'health versus the economy' framing

Wikipedia

entertainment

explore

entertainment